title: Possible role of PGRMC1 in breast cancer development.
abstract: Hormone therapy may increase the risk of breast cancer. Thus, especially the addition of synthetic progestins may play a decisive role according to the results of clinical studies. Overexpression of a special receptor, i.e. the progesterone receptor membrane component-1 (PGRMC1), may offer a potential new pathway to explain the observed increase in breast cancer risk in the combined arm of the Women's Health Initiative. PGRMC1 is expressed in breast cancer tissue and may be important in tumorigenesis. The expression of PGRMC1 in breast cancer tissue is significantly different from that in normal mammary glands. Certain synthetic progestins can increase the proliferation of PGRMC1-overexpressing breast cancer cells and may thus be involved in tumorigenesis, while progesterone and certain synthetic progestins such as nomegestrol or chlormadinone acetate react neutrally. Our investigations point towards an important role of estrogen receptor-α in the signaling cascade, resulting in the proliferative effect induced by progestins. Thus, activation of PGRMC1 may explain the increased breast cancer risk observed during treatment with certain progestins. Very recently, PGRMC1 was investigated in serum samples of lung cancer patients and matched healthy patients; significantly higher concentrations were shown in the cancer patients. Therefore, PGRMC1 might be a predictor for other cancers as well but, according to clinical trials, its importance for a possible screening tool, particularly for breast cancer risk during hormone therapy, seems of interest.
authors.affiliation: University Women's Hospital , Düsseldorf , Germany.
authors.forename: H
authors.initials: H
authors.lastname: Neubauer
authors.forename: Q
authors.initials: Q
authors.lastname: Ma
authors.forename: J
authors.initials: J
authors.lastname: Zhou
authors.forename: Q
authors.initials: Q
authors.lastname: Yu
authors.forename: X
authors.initials: X
authors.lastname: Ruan
authors.forename: H
authors.initials: H
authors.lastname: Seeger
authors.forename: T
authors.initials: T
authors.lastname: Fehm
authors.forename: A O
authors.initials: AO
authors.lastname: Mueck
mesh_terms: D001943:Breast Neoplasms / Q000737:chemistry / Q000209:etiology* / Q000473:pathology; D049109:Cell Proliferation / Q000187:drug effects; D047628:Estrogen Receptor alpha / Q000502:physiology; D004967:Estrogens / Q000494:pharmacology; D005260:Female; D006801:Humans; D061986:MCF-7 Cells; D008565:Membrane Proteins / Q000032:analysis / Q000502:physiology*; D017698:Postmenopause; D045167:Progesterone Congeners / Q000009:adverse effects / Q000494:pharmacology; D011980:Receptors, Progesterone / Q000032:analysis / Q000502:physiology*; D012307:Risk Factors; D015398:Signal Transduction; D016387:Women's Health
chemical_list: D047628:Estrogen Receptor alpha; D004967:Estrogens; D008565:Membrane Proteins; C115296:PGRMC1 protein, human; D045167:Progesterone Congeners; D011980:Receptors, Progesterone